The claims defining the invention are as follows:

1. Use of a 5,6- or 6,7-epoxy-tigliane compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for promoting wound healing of an existing wound in a subject.

2. Use according to claim 1 wherein the promoting wound healing comprises increasing the rate of wound healing of an existing wound.

3. Use according to claim 1 wherein the promoting wound healing comprises reducing scarring in the wound tissue of an existing wound.

4. Use according to any one of claims 1 to 3 wherein the promoting wound healing comprises both increasing the rate of wound healing and reducing scarring in wound tissue of an existing wound.

5. Use according to any one of claims 1 to 4 wherein the promoting wound healing comprises improving the cosmetic outcome of the ~~healed~~ existing wound upon healing.

6. Use according to any one of claims 1 to 5 wherein the wound is a chronic wound or~~,~~ an acute wound~~ or an existing wound~~.

7. Use according to any one of claims 1 to 6 wherein the epoxy-tigliane compound is in the form of a plant extract.

8. Use according to claim 7 wherein the plant extract is obtainable from a plant which is a *Fontainea* species or a *Hylandia* species.

9. Use according to any one of claims 1 to 8 wherein the epoxy-tigliane compound is a compound of formula (I):

17. Use according to any one of claims 9 to 16 wherein R_8 is $-OC(O)C_{1-15}$alkyl, $-OC(O)C_{2-15}$alkenyl, $-OC(O)C_{2-15}$alkynyl or –C(O)aryl where the aryl group is optionally substituted.

18. Use according to any one of claims 9 to 17 wherein R_9 and R_{10} are independently $-C_{1-3}$alkyl.

19. Use according to any one of claims 9 to 18 wherein R_{11} and R_{12} form an epoxide and R_{13} is -OH, $-OC(O)C_{1-6}$alkyl, $-OC(O)C_{2-6}$alkenyl or $-OC(O)C_{2-6}$alkynyl.

20. Use according to any one of claims 9 to 18 wherein R_{12} and R_{13} form an epoxide and R_{11} is -OH, $-OC(O)C_{1-6}$alkyl, $-OC(O)C_{2-6}$alkenyl or $-OC(O)C_{2-6}$alkynyl.

21. Use according to any one of claims 9 to 20 wherein R_{15} is hydrogen, $-C(O)C_{1-6}$alkyl, $-C(O)C_{2-6}$alkenyl or $-C(O)C_{2-6}$alkynyl.

22. Use according to any one of claims ~~8~~ 9 to 21 wherein R_{14} is hydrogen.

23. Use according to any one of claims 9 to 22 wherein R_{16} is hydrogen.

24. Use of a 5,6- or 6,7-epoxy-tigliane compound in the manufacture of a medicament for preventing excessive scarring in a healing wound.

~~25. Use according to claim 24 wherein the excessive scarring is a keloid or hypertrophic scar.~~

~~26~~25.A compound selected from the group consisting of:

12-hexanoyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 5);

12-acetyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 6);

12-propanoyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 7);

12-butanoyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 8);

12-[(2*E*,4*E*)-(6,6-dimethoxyhexa-2,4-dienoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 9);

12-[(2*E*,4*E*)-6-oxohexa-2,4-dienoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 10);

12-[(2*E*,4E)-6,7-dihydroxydodeca-2,4-dienoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 11);

12-[(2*E*)-4,5-dihydroxy-deca-2-enoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 12);

12-tigloyl-13-(2-methylpropanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 13);

12-[(2*E*)-3-methylthioprop-2-enoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 14);

12-(2-methylprop-2-enoyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 15);

12-[(2*E*,4*E*)-hexa-2,4-dienoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 16);

12-[(2*E*,4*E*)-8-oxododeca-2,4-dienoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound17);

12-[(2*Z*,4*E*)-deca-2,4-dienoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 18);

13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 19);

12-[(2*E*)-but-2-enoyl]-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 20);

12-tigloyl-13-butanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 21);

12-(3-butenoyl)-13-nonanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 22);

12,13-di-(2*E*,4*E*)-hex-2,4-enoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 46);

12-hexanoyl-13-[2-(N-methylanthraniloyl)]-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 47)

12-acetyl-13-[2-(N-methylanthraniloyl)]-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 48);

12,13-di-heptanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 49);

12-myristoyl-13-acetyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 50);

12-myristoyl-13(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 51);

12-(2-methylbutanoyl)-13-acetyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 52); and

12-hydroxy-13-hexanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 53);

12,13-di-(3-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one (Compound 60`);

or a pharmaceutically acceptable salt thereof.

~~27~~26. A pharmaceutical composition comprising a compound of claim ~~26—~~25 or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient.